

RECEIVED
CENTRAL FAX CENTER

OCT 30 2006

REMARKS

In the instant application, claims 14, 15, 23, and 25 have been cancelled. Claims 1-12, 24, and 26 have been withdrawn from consideration. Claims 1-13, 26-22, 24, and 26 are currently pending.

Rejection under 35 U.S.C. § 112, first paragraph-Written Description

Claims 13-23 and 25 stand rejected under 35 U.S.C. § 112, first paragraph as allegedly containing subject matter which was not described in the specification in a way as to reasonably convey to one skilled in the art that the inventor has possession of the claimed invention. Claim 13 has been amended to recite a method for preparing a compound comprising a reaction according to equation X (defined in the claim) using an anti-Kazlauskas lipase that is at least 80% identical to sequence SEQ ID NO 2. Support for the amendment to claim 13, specifically equation X, can be found, for example, on page 27 and 28 of the application. Further, support for providing an anti-Kazlauskas lipase that is at least 80% identical to sequence SEQ ID NO 2 can be found, for example, on page 6, line 19 to page 7, line 1 of the specification. Moreover, the amended claim language has been adopted from what the Office Action has indicated as being disclosed in the specification. *See Office Action, page 4.* As such, it is submitted that the present amendment to claim 13 overcomes the instant rejection. Withdrawal of such is respectfully requested.

Rejection under 35 U.S.C. § 112, first paragraph-Enablement

Claims 13-23 and 25 stand rejected under 35 U.S.C. § 112, first paragraph as allegedly not be enabled by the disclosure. Claim 13 has been amended as set forth above. With this amendment, the scope of claim 13 is now commensurate with the disclosure. Again, the claim amendment was adopted from what the Office Action has indicated as being enabled by the specification. *See Office Action, page 5.* As such, it is submitted that the present amendment to claim 13 overcomes this rejection. Withdrawal of such is respectfully requested.

BEST AVAILABLE COPY

Rejection under 35 U.S.C. § 112, second paragraph


Claims 13-23 and 25 have been rejected under 35 U.S.C. § 112, second paragraph as allegedly being indefinite. The Office Action takes objection to the use of the phrase "biological activity" within claim 13. Claim 13 has been amended to remove such language. Further, claim 13 has been amended in accordance with the language suggested in point 9 of the Office Action. *See Office Action, page 7.* As such, it is submitted that the amendment overcomes this rejection. Withdrawal of such is respectfully requested.

Claims 14, 15, 23, and 25 have been cancelled, thereby rendering any rejection of these claims moot. Claims 16-22, either directly or indirectly, depend from claim 13 and are now in condition for allowance for at least the same reasons as set forth with respect to claim 13. Withdrawal of the rejection of these claims is respectfully submitted.

In view of the foregoing, claims 13 and 16-22 are now in condition for allowance. A response to this Amendment in the form of a Notice of Allowability is hereby solicited.

Respectfully submitted,

By



Michael A. Miller
Attorney for Applicants
Reg. No. 50,732

October 30, 2006

LANXESS Corporation
111 RIDC Park West Drive
Pittsburgh, Pennsylvania 15275-1054
(412) 809-2232
FACSIMILE PHONE NUMBER:
(412) 809-1054